Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$20.25 CAD
Change Today +0.04 / 0.20%
Volume 725.0
As of 3:53 PM 11/26/15 All times are local (Market data is delayed by at least 15 minutes).

trillium therapeutics inc (TR) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - C$37.27
52 Week Low
12/17/14 - C$7.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

trillium therapeutics inc (TR) Related Businessweek News

No Related Businessweek News Found

trillium therapeutics inc (TR) Details

Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. Its primary program is SIRPaFc, an antibody-like fusion protein, which blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system. The company also develops CD200 mAb, a human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by various hematopoietic and solid tumors. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada.

18 Employees
Last Reported Date: 04/1/15
Founded in 2004

trillium therapeutics inc (TR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$390.0K
Chief Financial Officer
Total Annual Compensation: C$218.8K
Chief Development Officer
Total Annual Compensation: C$205.0K
Chief Scientific Officer
Total Annual Compensation: C$270.0K
Compensation as of Fiscal Year 2014.

trillium therapeutics inc (TR) Key Developments

Trillium Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Trillium Therapeutics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported net loss and comprehensive loss for the period of CAD 1,505,979 or CAD 0.21 per share compared to CAD 2,526,527 or CAD 0.60 per share for the same period ended September 30, 2014. Net finance loss was CAD 4,170,381 compared to a CAD 63,522 for the same quarter ended September 30, 2014. For nine months, the company reported net loss and comprehensive loss for the period of CAD 11,744,856 or CAD 1.84 per share compared to CAD 8,666,958 or CAD 2.08 per share for the same period ended September 30, 2014. Net finance loss was CAD 4,232,458 compared to a CAD 231,517 for the same quarter ended September 30, 2014. Cash used in operating activities was CAD 13,699,304 compared to a CAD 5,409,026 for the same quarter ended September 30, 2014. Purchase of property and equipment was CAD 522,133 compared to a CAD 144,196 for the same quarter ended September 30, 2014.

Trillium Therapeutics Inc. Presents at BIO-Europe 2015, Nov-02-2015

Trillium Therapeutics Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Trillium Therapeutics Inc. Complete Manufacture of Clinical-Grade Drug Product

Trillium Therapeutics Inc. announced that it has completed the manufacture of clinical-grade drug product, concluded a comprehensive IND-enabling non-clinical safety assessment program, and has proposed a design for its first-in-human clinical trial with TTI-621 (SIRPaFc). The company plans to conduct a Phase I trial with a dose-escalation stage that will enroll patients with relapsed or refractory lymphoma who are transfusion independent with relatively normal baseline blood counts, thus better enabling characterization of potential changes in hematologic parameters that could occur upon CD47 blockade. Once the optimal dose and schedule of TTI-621 administration have been established, the company expects to study safety and anti-tumor activity in a variety of expansion cohorts of patients. These will include patients with acute myeloid leukemia, myelodysplastic syndrome, as well as several other advanced hematologic malignancies. Additional in vitro and in vivo preclinical studies have been completed. These have demonstrated that TTI-621 has potent anti-tumor activity across a range of hematological tumors, and have provided guidance for the expansion cohorts in the first-in-human clinical study. The company expects to present some of these data at an upcoming scientific meeting. The company also continues to explore the therapeutic potential of TTI-621 in a variety of solid tumor models, both as monotherapy and in combination with other therapeutic agents. Based on the results of these studies, as well as on third party data reported in the literature, additional clinical trials will be designed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TR:CN C$20.25 CAD +0.04

TR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TR.
View Industry Companies

Industry Analysis


Industry Average

Valuation TR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TRILLIUM THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at